A cancer therapeutic agent according to the present invention comprises a
combination of compound A described below, or a pharmaceutically
acceptable salt thereof, and compound B described below, or a
pharmaceutically acceptable salt thereof: Compound A: compound A1
represented by formula (1) below, or water-soluble prodrug A2 thereof;
Compound B: at least one type of compound selected from the group
consisting of a platinum-type anticancer compound, a gemcitabine-type
compound, a 5-FU-type compound, a taxane-type compound, a vinca
alkaloid-type compound, an anticancer tyrosine kinase inhibitor compound,
and an anticancer monoclonal antibody;
##STR00001##
(wherein, R.sup.11 represents a hydrogen atom, a halogen atom or a C1-C6
alkyl group;R.sup.12 represents a hydrogen atom, a halogen atom, a C1-C6
alkyl group, or a hydroxyl group;R.sup.21 represents a hydrogen atom or a
C1-C10 alkyl group which may comprise one to three substituents selected
from Group B described below: Group B: a C1-C6 alkoxy group, a hydroxy
group, a halogen atom, an amino group, a mono-C1-C6 alkylamino group, a
di-C1-C6 alkylamino group, a C3-C7 cycloalkyl group, a heterocycle, and
an aryl ring (the aryl ring may comprise one to three substituents
selected from the group consisting of a hydroxy group, a C1-C6 alkoxy
group, a halogen atom, an amino group, a mono-C1-C6 alkylamino group, and
a di-C1-C6 alkylamino group); andR.sup.22 represents a hydrogen atom, an
amino group, or a C1-C6 alkyl group that may comprise one to three
substituents selected from Group C described below, a C1-C6 alkoxy group
that may comprise one to three substituents selected from Group C
described below, a C1-C6 alkylthio group that may comprise one to three
substituents selected from Group C described below, a mono-C1-C6
alkylamino group that may comprise one to three substituents selected
from Group C described below, or a di-C1-C6 alkylamino group that may
comprise one to three substituents selected from Group C described below:
Group C: a C1-C6 alkoxy group, a hydroxy group, a halogen atom, an amino
group, a C3-C7 cycloalkyl group, a heterocycle, and an aryl ring (the
aryl ring may comprise one to three substituents selected from the group
consisting of a hydroxy group, a C1-C6 alkoxy group, an amino group, a
mono-C1-C6 alkylamino group, and a di-C1-C6 alkylamino group).
